N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Details for Australian Patent Application No. 2010292225 (hide)

Owner Amgen Inc.

Inventors Payton, Marc; Kendall, Richard

Agent Shelston IP

Pub. Number AU-A-2010292225

PCT Pub. Number WO2011/031842

Priority 61/241,527 11.09.09 US

Filing date 9 September 2010

Wipo publication date 17 March 2011

International Classifications

A61K 31/502 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

12 April 2012 PCT application entered the National Phase

  PCT publication WO2011/031842 Priority application(s): WO2011/031842

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010292231-An system and method for displaying, navigating and selecting electronically stored content on a multifunction handheld device

2010292224-Edible surface-modifying particles and methods for their manufacture